Qualitative and quantitative comparison of the cardiac effects of encainide and its three major metabolites in the dog.
We have evaluated the electrophysiologic effect of encainide and its three major metabolites, O-demethyl encainide, 3-methoxy-O-demethyl encainide and N-demethyl encainide in an anesthetized dog model. Our results support previous reports that O-demethyl encainide and 3-methoxy-O-demethyl encainide are both more potent than encainide in the depression of conduction. We also have shown that N-demethyl encainide is of about equal potency to encainide. Whereas the major differences between these compounds is primarily one of potency, there are some qualitative differences. Although O-demethyl encainide did not change the ventricular or atrial effective refractory periods significantly, 3-methoxy-O-demethyl encainide and N-demethyl encainide prolonged both. Encainide increased the atrial effective refractory period but did not produce significant changes in the ventricular refractory period. These data support previous suggestions of an important role for these metabolites as modulators of the clinical efficacy of encainide.
D000813:Anilides / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001283:Atrioventricular Node / Q000187:drug effects; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D016700:Encainide / Q000031:analogs & derivatives; D005260:Female; D006321:Heart / Q000187:drug effects*; D008297:Male; D012032:Refractory Period, Electrophysiological / Q000187:drug effects
D000813:Anilides; D000889:Anti-Arrhythmia Agents; C033635:O-demethylencainide; C049330:N-demethylencainide; C033636:3-methoxy-O-demethylencainide; D016700:Encainide